Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
复制标题
晚期胰腺癌特异性免疫治疗的临床结果：系统评价和荟萃分析
DOI：
10.1155/2017/8282391
复制
发表时间：
2017
影响因子：
4.1
通讯作者：
Qi XS
中科院分区：
文献类型：
--
作者：
Chen J;Xiao-Zhong G;Qi XS
特异性免疫治疗，包括自体肿瘤细胞疫苗和肿瘤抗原特异性单克隆抗体，是PC患者的重要治疗方法。为了评估PC特异性免疫治疗的临床结局，我们对相关已发表的临床试验进行了系统回顾和荟萃分析。将特异性免疫治疗的效果与非特异性免疫治疗的效果进行比较，并对总生存期（OS）、免疫应答数据和血清癌症标志物数据进行荟萃分析。采用随机效应模型进行汇总分析。我们发现，使用特异性免疫疗法的PC患者的OS显著改善，并且还观察到免疫应答改善。结论：特异性免疫治疗在延长PC患者生存期和增强免疫应答方面具有上级优势。
Specific immunotherapies, including vaccines with autologous tumor cells and tumor antigen-specific monoclonal antibodies, are important treatments for PC patients. To evaluate the clinical outcomes of PC-specific immunotherapy, we performed a systematic review and meta-analysis of the relevant published clinical trials. The effects of specific immunotherapy were compared with those of nonspecific immunotherapy and the meta-analysis was executed with results regarding the overall survival (OS), immune responses data, and serum cancer markers data. The pooled analysis was performed by using the random-effects model. We found that significantly improved OS was noted for PC patients utilizing specific immunotherapy and an improved immune response was also observed. In conclusion, specific immunotherapy was superior in prolonging the survival time and enhancing immunological responses in PC patients.